The impact of modulating the expression of embryonic globin genes is growingly being considered in the development of protocols for thalassemia treatment.91,92 These data will be considered together with the expression of known γ-globin gene repressors (e.g. BCL11A, MYB, LYAR, and ZBTB7A).93, , –96 Preliminary data on BCL11A and LYAR downregulation were obtained using ErPCs isolated from sirolimus-treated patients (unpublished data from Cristina Zuccato). The gene discussed is MYB; the disease is thalassemia.